That's correct. I mean antibodies that arise from our immune system fighting the disease. If leronlimab allows our immune system to fight the disease, it should develop antibodies, correct? I'm not saying that we use leronlimab in place of vaccines, rather those who need it to recover should develop antibodies, that is what I was asking.

I understand about not giving a weekly injection, and that's not what I'm advocating, however, those who get covid-19 and recover, their antibodies last for a while don't they? Shouldn't the antibodies that arise from using leronlimab last just as long? How long do these antibodies last compared to the vaccines?

Will Leronlimab allow immunity to develop? If an individual is given leronlimab, which then allows the immune system to fight whatever variant, does the individual develop anti-bodies to covid-19? If this is true, wouldn't this be preferable than having a vaccine which alters our immune system?

If that figure comes to fruition, that alone is more than 5 million a month revenue. I have my sell price set at $10. I'm going to have to adjust it up a lot sooner than I expected.

If this sp is to be supported, a pr won't cut it unless it has the actigraph data from PDD trial and it needs to be outstanding. A article in a peer reviewed journal supporting this would be a nice capper, otherwise the sp continues south.

It's on their twitter account.

$IQST Services, next week will update about our products and projects #IoT #evbatteries #visadebitcard #fintech #blockchain #telecom ⁦@Etelix⁩ pic.twitter.com/f3dyWQ27OD

— iQSTEL Inc. (OTCQX: IQST) (@IQstel) February 5, 2021

I think a small pullback would be good. I am with you as I bought at .09 and am loving the sp action, however some consolidation at this point I think would be a good thing. I also believe that this will be dollars this year, but a slow steady climb, with higher highs, and higher lows I feel is the preferred way. Build a base, I am here for the long haul, and have set a $10 sale price on my shares, which I hope to have to adjust up within a couple of years. I think the best for IQST would be for investors, not traders to jump in, realizing that the potential here is tremendous, and getting in at this level is rare opportunity indeed.

Thanks Crawfors, you are exactly right. I've been here since mid Dec and I got in at .09, and am very happy with the price where it is. I really hope it doesn't shoot up too fast, because I believe it will fall just as quick with the traders jumping in. If there is a steady slow increase with the appropriate amount of consolidation, along with strong revenue and income reports, then I feel that it will take longer than a few months to get uplisted, but I'm willing to wait.

What happens to sp if CD12 is good? If in the next couple of days, the price appreciates because of the chatter about the shorts, and then stat sig for CD 12, do we get a sell the news reaction? If the price is already double digits when positive news comes out, will there be a lot of people cashing in, or what?

I feel the next month will be exciting! Very possible, and in my opinion likely EUA and Nasdaq uplist, Hang on, I think we hit double digits before end of Feb.

New to COUV and I agree. Also what is not thought of very much is the drain on the electric grid if everybody is recharging at the same time. I read the direction that the company wants to take regarding having the charging stations connected to C-ion batteries which charge up at off peak hours, then EV's recharge off them at stations during the day. Very forward thinking.

I wonder if the EV direction that IQST is thinking about might be Corporate Universe. COUV just aquired pretty much all the C-ion battery technology, and just recently said in a pr that they hired some lawyers to get their house in order for a merger in a few weeks. I wonder if one has anything to do with the other.

If stat sig how soon EUA? What is anyone's prediction how soon lenronlimab gets EUA if stat sig results, and what is a honest guess regarding sp if this happens?

Say what you will, but I invested 20k at the end of March 2020 and bought for .97 after first eind. I sold a bunch 1st of July, paid off my house, bought back in 1st of Nov cause I had stock from employee stock purchase plan that matured Oct 31, and I plan to stick around a while. I'm just an hourly worker who made twice my yearly wages, I'm not mad, I'm happy and I feel it will help me retire early. I'm not greedy, and I care for those who will benefit from leronlimab.

It's not silence, just tired of all bs. Nader said he expects data release next week and as I heard in his last statement that he was excited, this sounds great to me. He appeared tired, but I'm sure he's put in a lot of hours on CD12. I'm not here to trade, but to invest, and I heard plenty to look forward to for the next couple years

His last statement was that he was excited for CD12 data release. I thought he looked tired, and he even stated everything pretty much had taken a back seat to CD12, possibly even sleep. I think if it is stat sig, leronlimab gets EUA quick, and once BLA is filed, then approved, I believe we could hit $50 by end of year.
All imo

I was lucky and got in at .09 per share in mid Dec. Hard to believe that in 6 weeks I've already quadrupled and more. I don't plan on selling either until it get's to $10 plus, as I believe we will see that in <2 years with the plans I see being put forth by the company. Management is doing a good job, and are transparent with what they intend to do in the future. Sure not like most OTC stocks I've seen.

Thank you for your time in writing this. I have invested in other companies that have had run up's like this and then experienced short attacks to take advantage of the stop losses put in by new retail investors. What do you think will be the chance of that happening here?

I agree, and I would expect with the opportunities for revenue that they are bringing into their portfolio this year, I would expect there to be 6-7 million monthly revenue and it only be the beginning. Now with their debt restructured, I am hoping for serious net profit perhaps starting as early as this quarter, but at least by mid-year. This is a an awesome opportunity, and I realistically expect IQST to be trading in the $4-$5 dollar range in a year or two. I can wait that short while for that kind of return.

I really appreciate all that you have done dh, I'm a newbie to IQST, been here only a little over a month, got in at .09, right after they announced on 12-14 about possibly surpassing the 42 million revenue for the year, and 2nd 5 million dollar month. I couldn't believe how cheap the sp was and still is. Just a quick question, you have indication of forecast revenue of 60 million for 2021, yet the IQST hasn't updated their page, and it reflects a 42 million forecast for 2020. I wonder about things like this, since it been almost a month, you would think that it's the kind of thing that someone would pay attention to with this kind of company.

I agree and have said this many times. Institutions will not be interested until revenue, which allows traders to make hay. I expect the sp to drop in the next week or two to below $5, and then it will get pumped up again to +$6. The 20% swings is what makes this a favorite of channeling stock traders.

I personally feel it won't happen until Avatar results are in.

If new variants evolve to escape body's own immunity, can leronlimab still be effective?
http://www.ipharminc.com/new-blog/2021/1/20/the-rise-of-coronavirus-variants-early-signs-of-immune-escape

Well written and I agree with you. I believe that what will influence investors to buy at higher prices is profit from sales. We haven't seen it yet and that is what I believe is causing some people to sell at these lower prices allowing the shorts to profit. There have been a lot of positive developments lately that point to future revenue and hopefully profit, but we're not there yet, and until that happens I believe we will see volitiliy in share price.

Has a limit of available leronlimab been mentioned? I know NP has said they could get more if needed, but looking at potential world wide demand, as vaccine rollout is hitting snags such as not having the second shot, how many doses can really be expected this year if EUA is granted?

I have a question for those in the know. Does CYDY have to show stat sig results on CD12 to get EUA. From my understanding it wasn't for other therapeutics that are now in use at hospitals. What is the criteria for EUA?

I compared ALPP with IQST as well, and I was surprised how much more potential as well as a better balance sheet there is for IQST. If investors start looking close, we could hit 5 bucks by EOY.

It would be very nice to see what happened to ALPP do so to IQST. I hope however we wouldn't see quite such a pullback, if there is a good profit margin to go with increasing revenue.

My cost basis is slightly lower, however I came across CYDY just after I read about the first EIND at the end of March. I got in just under a buck, but I have been "averaging up" every so often. I did not sell when it went to $10 as I am not one to time the market and I believe that it will have great impact on human well being in the next few years.

If they report profits at end of March with revenue 15+ million for quarter, you don't think that will get exposure? If it's going to take 100 million, that could take a couple more years.

NP mentioned that they could sell it now, but it seemed he is waiting on FDA. If it seems to him that they are dragging their feet he may forget the niceties and just sign a deal. If he can get revenue flowing, and pr it when shorts least expect it, I think it would be something he would do.

I agree! BP would be smart to do a buyout at 100 billion if we get approval for HIV, because once we get approval for NASH and cancer it will cost 200 billion or more.

So why is it so cheap?? I would think that profit is coming this year, so what keeps the sp depressed?

I'll be excited it it amounts to 1/2 that amount.

If I recall correctly, NP said that there had been 100 million shares authorized and could sell a few mill each month to pay the bills. He said it wouldn't be much dilution as he appeared to indicate he expected revenues soon.

I think that any sell off will be because traders will unload thinking they can get in 2-4 weeks from now at a cheaper price. I'm not so sure all the manipulation is due to shorts only, as NP has made it easy to trade in and out with these CC's. Personally I'm not doing that, and may use any significantly lower price to add more as I believe this will be at least a 10 bagger in a year's time.

I see where they had net income on the 10Q for June, but not the most recent one. When can we expect the next 10Q?

Absolutely! What will happen if Philippines want all of leronlimab? Then MHRA and Canada and FDA? How can Cytodyn and Samsung meet the demand. Brazil and the rest of the world will have to stand in line

Can you just imagine the sp if what NP put forth for 2021 comes to fruition? Wow!

I listened to the call and I agree. I am here for the long term so I am looking forward to the next year or more. It seems as if NP does have a lot of irons in the fire, but he did seem more focused on covid. I liked that he seemed confident that CD12 results by end of Jan.